SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-042692
Filing Date
2021-08-16
Accepted
2021-08-16 09:22:24
Documents
13
Period of Report
2021-08-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea145867-8k_unicycive.htm   iXBRL 8-K 25827
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED AUGUST 16, 2021 ea145867ex99-1_unicycivethe.htm EX-99.1 45283
  Complete submission text file 0001213900-21-042692.txt   250018

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE uncy-20210816.xsd EX-101.SCH 3027
4 XBRL LABEL FILE uncy-20210816_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE uncy-20210816_pre.xml EX-101.PRE 22360
6 EXTRACTED XBRL INSTANCE DOCUMENT ea145867-8k_unicycive_htm.xml XML 3596
Mailing Address 5150 EL CAMINO REAL, SUITE A-32 LOS ALTOS CA 94022
Business Address 5150 EL CAMINO REAL, SUITE A-32 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 211174954
SIC: 2834 Pharmaceutical Preparations